JP3126583B2 - Burn treatment agent, method for producing the same, and treatment method using the same - Google Patents
Burn treatment agent, method for producing the same, and treatment method using the sameInfo
- Publication number
- JP3126583B2 JP3126583B2 JP06025840A JP2584094A JP3126583B2 JP 3126583 B2 JP3126583 B2 JP 3126583B2 JP 06025840 A JP06025840 A JP 06025840A JP 2584094 A JP2584094 A JP 2584094A JP 3126583 B2 JP3126583 B2 JP 3126583B2
- Authority
- JP
- Japan
- Prior art keywords
- sesame oil
- weight
- agent
- burn
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【０００１】[0001]
【産業上の利用分野】この発明は、ヒトを含む温血動物
の熱傷治療剤に関し、さらに詳しくは、ある種の植物お
よび動物の抽出物を有効成分として含有する熱傷治療剤
およびその製造方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a remedy for burns of warm-blooded animals including humans, and more particularly to a remedy for burns containing certain plant and animal extracts as an active ingredient and a method for producing the same. .
【０００２】[0002]
【従来の技術】１９３０年代に、外傷、ことに熱傷の治
療法として、乾式の抗感染治療方法、ついで外科的皮膚
移植による治療方法を相次いで施すことが行なわれた。
それまで、生体表面積の３０％を超える熱傷の場合は治
療が極めて困難であったが、かかる治療法を適用するこ
により、長年の宿題が解決されるに至った。ついで、熱
傷ショック罹病率の研究により、大面積熱傷の処置に関
して有用な指針を得ることができ、熱傷の臨床的治療シ
ステムが日常的に行なわれ、確立するに至った。かかる
治療法を、本明細書中では「乾式治療法」と称すること
にする。2. Description of the Related Art In the 1930s, dry anti-infective treatment followed by surgical skin transplantation was successively applied as a treatment for trauma, particularly burns.
Until then, it was extremely difficult to treat burns that exceeded 30% of the body surface area, but applying such treatments has long solved homework. The study of burn shock morbidity could then provide useful guidance on the treatment of large area burns and led to a routine clinical burn treatment system established. Such treatment is referred to herein as "dry treatment."
【０００３】[0003]
【発明が解決しようとする課題】しかるに、１９７０年
代に至って、かかる乾式治療法に対する信頼性は実験的
研究により、理論的にも、また実際的にも疑いを投げか
けられるようになった。第一の理由は、この治療法では
十分に良好な治療効果が得られないからである。乾式治
療法を受けた患者は厳しい苦痛に耐えねばならず、よし
んば、治療に成功したとしても精神的、肉体的に深い傷
跡を残すことになる。本発明の発明者は、かかる乾式治
療法は理論的な根拠を欠き、また治療方法も誤っている
と考えている。乾式治療法は、熱で損傷した皮膚とうっ
血組織とは早晩、懐死に到るのだから、乾燥させて懐死
を早めてやり、もって感染を防御し、そして皮膚移植が
可能な状態にもっていこうというのが基本的な考え方で
ある。However, up to the 1970's, the reliability of such dry treatments has been questioned theoretically and practically by experimental studies. The first reason is that this treatment does not provide a sufficiently good therapeutic effect. Patients who receive dry treatment must endure severe pain and, if successful, leave deep scars, both mentally and physically. The inventor of the present invention believes that such dry treatments lack theoretical grounds and that the treatments are incorrect. Dry treatment is a technique that causes heat-damaged skin and congested tissue to die sooner or later, so let's dry it, get rid of it early, prevent infection, and get skin transplantation ready That is the basic idea.
【０００４】しかし、この分野の当業者は、乾式治療法
には多々欠点があることを熟知している。たとえば、真
皮を欠く創傷が外気にさらされると、空気により直接に
損傷をうける。患者の体液が大量に失われる。大量の抗
生物質の投与により皮膚の再生が阻害され、かさぶたの
除去や皮膚移植により、しばしば医原性の傷害が生じる
等々である。本発明の目的は、皮膚が熱傷を受けて生ず
るうっ血部位組織の治癒、再生に有効な薬剤組成物を提
供し、既存の治療法に内在する欠点を克服するこにあ
る。本発明の他の目的は、かかる薬剤組成物の製造方法
を提供することにある。本発明の更に別の目的は、薬剤
組成物を創傷治療用に適用することにある。[0004] However, those skilled in the art are well aware that dry therapy has a number of disadvantages. For example, when a wound that lacks the dermis is exposed to the open air, it is directly damaged by air. Large amounts of patient fluid are lost. Administration of large amounts of antibiotics inhibits skin regeneration, scab removal and skin transplantation often results in iatrogenic injuries, and so on. SUMMARY OF THE INVENTION It is an object of the present invention to provide a pharmaceutical composition effective for healing and regenerating congestion site tissue caused by burns to the skin, and to overcome the drawbacks inherent in existing therapies. Another object of the present invention is to provide a method for producing such a pharmaceutical composition. Yet another object of the present invention is to apply the pharmaceutical composition for treating wounds.
【０００５】[0005]
【課題を解決するための手段】本発明者は、伝統的な中
国医学を現代医学との両方を理論的な基礎として、「湿
式治療法」と称する、新たな熱傷治療法を企図した。湿
式治療法によれば、熱傷によるうっ血部位組織は再生可
能なものであると考える。それ故、医師は組織を保持し
傷害を減少する努力をしなければならない。熱傷組織
を、生理学的諸条件に合致する三次元の湿った環境にお
けば、懐死組織の除去と組織の再生に叶うことになる。
湿式治療法では、以下に詳述する新規な薬剤組成物が
使用される。すなわち、本発明によれば、薬剤全重量の
３〜１５部を占めるミツロウと、８５〜９７部を占める
ゴマ油抽出物とからなり、当該ゴマ油抽出物は、原料乾
物として、薬剤全量の各２〜１０部を占める黄苓、黄
蓮、黄柏、地龍および罌粟穀の抽出物であることを特徴
とする薬剤組成物が提供される。この薬剤組成物は、
０．２０重量％またはそれ以上のβ−シトステロールを
含有する。SUMMARY OF THE INVENTION The present inventor has conceived of a new method of treating burns, called "wet treatment", using both traditional Chinese medicine and modern medicine as theoretical bases. According to the wet treatment method, the congested site tissue due to the burn is considered to be renewable. Therefore, physicians must strive to retain tissue and reduce injuries. If the burned tissue is placed in a three-dimensional moist environment that meets physiological conditions, it will be possible to remove the dead tissue and regenerate the tissue.
In wet therapy, novel pharmaceutical compositions, described in detail below, are used. That is, according to the present invention, it comprises beeswax occupying 3 to 15 parts of the total weight of the drug, and sesame oil extract occupying 85 to 97 parts of the sesame oil extract. A pharmaceutical composition is provided, which is an extract of Huangling, Huangren, Huangbashi, Jilong and Poppy, which occupies 10 parts. This pharmaceutical composition comprises:
Contains 0.20% by weight or more β-sitosterol.
【０００６】本発明で使用される黄苓は、上海科学技術
出版の「中国薬用原料」（１９８８年発行、以下に参照
される）２０１７〜２０２１頁に記載のＬａｂｉａｔａ
ｅ科に属するＳｃｕｔｅｌｌａｒｉａ ｖｉｓｃｉｄｕ
ｌａ Ｂｇｅ，Ｓ．ｂａｉｃａｌｅｎｓｉａ Ｇｅｏｒ
ｇｉ，Ｓ．ａｍｏｅｎａ Ｃ．Ｈ．Ｗｒｉｇｈｔ，Ｓ．
ｒｅｈｄｅｒｉａｎａ Ｄｉｅｌｓ，Ｓ．ｉｋｏｎｎｉ
ｋｏｖｉｉ Ｊｕｚ，Ｓ．ｌｉｋｉａｎｇｅｎｓｉｓ
ＤｉｅｌｓおよびＳ．ｈｙｐｅｒｉｃｉｆｏｌｉａ Ｌ
ｅｖｌから選ばれる植物の根が使用される。黄蓮は同２
０２２〜２０３０頁に記載の、Ｒａｎｕｎｃｕｌａｃｅ
ａｅ科に属するＣｏｐｔｉｓ ｄｅｌｔｏｉ ｄｅａ
Ｃ．Ｙ．Ｃｈｅｎｇ ｅｔ Ｈｓｉａｏ，Ｃ．ｃｈｉｎ
ｅｎｓｉｓ Ｆｒａｎｃｈ，Ｃ．ｏｍｅｉｅｎｓｉｓ
（Ｃｈｅｎ）Ｃ．Ｙ．ＣｈｅｎｇおよびＣ．ｔｅｅｔｏ
ｉｄｅｓ Ｃ．Ｙ．Ｃｈｅｎｇから選ばれる植物の根が
使用される。[0006] Huangling used in the present invention is Labiata described in "Chinese Pharmaceutical Ingredients" (published in 1988, see below), Shanghai Science and Technology Press, pp. 2017-2021.
Scutellaria vicidu belonging to family e
la Bge, S.M. baicalensia geor
gi, S .; amoena C.A. H. Wright, S.M.
rehderiana Diels, S .; ikonni
kovii Juz, S.M. likeiangensis
Diels and S.M. hypericifolia L
The roots of a plant selected from evl are used. Yellow Lotus
Rununculus described on pages 022 to 2030
Coptis deltoi dea belonging to the family ae
C. Y. Cheng et Hsiao, C.I. chin
ensis Franc, C.I. omeiensis
(Chen) C.I. Y. Cheng and C.I. teato
ids C.I. Y. A plant root selected from Cheng is used.
【０００７】黄柏は、同２０３１〜２０３５頁に記載の
Ｒｕｔａｃｅａｅ科に属するＰｌｅｌｌｏｄｅｎｄｒｏ
ｎ ｃｈｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ，Ｐ．ａｍｕｒ
ｅｎｓｅ Ｒｕｐｒ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎ
ｅｉｄ ｖａｒ．ｇｌａｂｒｉｕｓｃｕｌｕｍ Ｓｃｈ
ｎｅｉｄ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ ｖ
ａｒ．ｏｍｅｉｅｎｓｅ Ｈｕａｎｇ，Ｐ．ｃｈｉｎｅ
ｎｓｅ Ｓｃｈｎｅｉｄ ｖａｒ．ｙｕｎｎａｎｅｎｓ
ｅ ＨｕａｎｇおよびＰ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎ
ｅｉｄ ｖａｒ．ｆａｌｃｕｔｕｍ Ｈｕａｎｇ から
選ばれる植物の樹皮が使用される。地龍はミミズであ
り、同２１１１〜２１１４に記載のＰｈｅｒｅｔｉｍａ
ａｓｐｅｒｇｉｌｌｕｍ（Ｅ．Ｐｅｒｒｉｅｒ）および
Ａｌｌｏｌｏｂｏｐｈｏｒａ ｃａｌｉｇｉｎｏｓａ
ｔｒａｐｅｚｏｉｄｅｓ（Ａｎｔ．Ｄｕｇｅｓ）から選
ばれ、乾燥もしくは生のミミズそのものが使用される。
罌粟穀はＰａｐａｖｅｒ ｓｏｍｎｉｆｅｒａｍ Ｌ．
すなわちケシであり、常法に従って、乾物が調製され
る。[0007] Huangkashiwa, Pellloadendro belonging to the family Rutaceae described in pp. 2031-2035.
n chinense Schneid, P .; amur
ense Rupr, P .; chinense Schn
eid var. glabriusculum Sch
neid, P .; chinense Schneid v
ar. omeiense Huang, P .; chine
nse Schneid var. yunnanens
e Huang and P.M. chinense Schn
eid var. bark of a plant selected from Falcutum Huang is used. The ground dragon is an earthworm, and Pheretima described in 1111-2114
aspergillum (E. Perrier) and Allolobophora caliginosa
It is selected from trapezoides (Ant. Duges), and the dried or raw earthworm itself is used.
The poppy cereal is Papaver somniferam L.
That is, it is a poppy, and a dry matter is prepared according to a conventional method.
【０００８】本発明の薬剤組成物は以下の手順に従い調
製される。すなわち、先ず、黄苓、黄蓮および黄柏を細
片化し、これを地龍および罌粟穀と混合する。ゴマ油を
１２０℃ないし１８０℃に加熱し、これに前記混合物を
加えて、同温度で３０ないし４５分間保つ。各原料のゴ
マ油に対する割合は、乾物重量比で２〜１０対１００で
ある。常温まで放冷したのち、ゴマ油抽出物を分取し、
残渣を捨てる。このように得られるゴマ油抽出物をミツ
ロウと十分に混合する。ミツロウとゴマ油抽出物の割合
は３〜１５％対８５〜９７％である。かくして得られる
薬剤組成物は淡黄色の軟膏状であり、水分および揮発成
分は０．０１％より少ない。液状にすると透明であり、
顕微鏡下で粒子を認めない。１９８５年中華人民共和国
局方補遺５１頁に記載の方法で測定した酸価は３．５８
±０．２０％であり、また同５１頁に記載の方法で測定
したケン化価は１７８±０．７％である。サーミスター
法で測定した初期軟化点は２１℃ないし２３℃であり、
そして、回転ボール型軟化点測定装置による最終軟化点
は４５℃ないし４９℃である。[0008] The pharmaceutical composition of the present invention is prepared according to the following procedure. That is, first, the yellowing, yellow lotus and yellow mulberry are shredded and mixed with ground dragon and poppy. The sesame oil is heated to 120 ° C to 180 ° C, to which the mixture is added and kept at the same temperature for 30 to 45 minutes. The ratio of each raw material to sesame oil is 2 to 10 to 100 in terms of dry matter weight ratio. After cooling to room temperature, the sesame oil extract is collected and
Discard the residue. The sesame oil extract thus obtained is thoroughly mixed with beeswax. The ratio of beeswax and sesame oil extract is 3-15% to 85-97%. The pharmaceutical composition thus obtained is in the form of a pale yellow ointment with less than 0.01% of water and volatile components. It is transparent when liquid,
No particles are observed under the microscope. The acid value measured by the method described in the supplementary page 51 of the People's Republic of China 1985 was 3.58.
The saponification value measured by the method described on page 51 is 178 ± 0.7%. The initial softening point measured by the thermistor method is 21 ° C to 23 ° C,
And, the final softening point by the rotating ball type softening point measuring device is 45 ° C. to 49 ° C.
【０００９】ゴマ油中の水分含量は０．０１ないし０．
１％の範囲内に、そしてミツロウ中のパラフィン含有は
２０％を超えないことが望ましい。ミツロウは通常は１
００℃ないし１８０℃に予熱して、ゴマ油抽出物と混合
される。本発明の薬剤組成物は、主としてヒトおよびそ
の他の温血動物の大規模の熱傷の治療に使用されるが、
その他、薬物によるヤケドにも使用される。更にまた、
外部潰瘍を含む種々の潰瘍、感染症による創傷、膣炎、
子宮頸部びらん、痔疾、褥瘡、通常の創傷、凍傷等の治
療にも使用される。本発明の薬剤は、傷部位に直接に、
約１ｍｍの厚さに塗布して使用される。傷部の鮮創は通
常は不要である。塗布４〜５時間後またはそれより後れ
て、傷部位は液状化して白色を帯びる。これにより、薬
物が傷部位に作用することがみてとれる。塗布は繰返し
行ってよい。もし、液状化物が多量のときは、緩やかに
拭い取り、薬剤を再び塗布し、傷が完全に治癒するまで
これを繰り返す。[0009] The water content in sesame oil is 0.01 to 0.5.
It is desirable that the paraffin content in the range of 1% and beeswax does not exceed 20%. Beeswax is usually 1
Preheat to 00-180 ° C and mix with sesame oil extract. Although the pharmaceutical composition of the present invention is mainly used for treating large-scale burns of humans and other warm-blooded animals,
It is also used for burns caused by drugs. Furthermore,
Various ulcers, including external ulcers, wounds due to infections, vaginitis,
It is also used to treat cervical erosion, hemorrhoids, pressure ulcers, normal wounds, frostbite, etc. The drug of the present invention is directly applied to the wound site,
It is used after being applied to a thickness of about 1 mm. Wounding of the wound is usually unnecessary. 4-5 hours or more after application, the wound site liquefies and becomes white. This shows that the drug acts on the wound site. The application may be repeated. If the liquefaction is large, gently wipe it off, apply the drug again, and repeat until the wound is completely healed.
【００１０】本発明は次のような利点を有する。すなわ
ち、本発明の薬剤組成物は純粋に天然の成分から成り、
これで以て全く新しい傷治療法、ことに熱傷治療法を行
うものである。本発明の薬剤組成物を塗布すると、傷部
は湿った状態に保たれるが、ふやけた状態とはならな
い。壊死した皮膚層に液状化して自然に除去される。か
くして、組織および傷表面における適度の排液がおこな
われる。本発明によるユニークな投与方法と薬剤の作用
とによって、有効成分が傷部位に常に適当な濃度で供給
され、それによって傷部位からの***物が連続的に除去
される。傷表面は外気から隔離されるので、それ以上刺
激をうけたり、傷が広がることはない。そして、代謝物
と***物は適宜に除去される。さらに、本発明の薬剤組
成物は、非麻薬的作用により苦痛をやわらげる効果を示
すものである。塗布５〜１０分後に、痛みは完全に止ま
るので、熱傷の治療における一番の問題が解決される。The present invention has the following advantages. That is, the pharmaceutical composition of the present invention consists of purely natural ingredients,
This gives a completely new wound treatment, especially a burn treatment. When the pharmaceutical composition of the present invention is applied, the wound is kept moist but does not become swollen. It liquefies into the necrotic skin layer and is naturally removed. Thus, adequate drainage at the tissue and at the wound surface is achieved. Due to the unique administration method and the action of the drug according to the present invention, the active ingredient is always supplied to the wound site at an appropriate concentration, thereby continuously removing the excrement from the wound site. The wound surface is isolated from the outside air, so it will not be irritated or spread. Then, metabolites and excretions are appropriately removed. Further, the pharmaceutical composition of the present invention exhibits an effect of relieving pain by a non-narcotic effect. After 5 to 10 minutes of application, the pain has completely ceased, thus solving the foremost problem in treating burns.
【００１１】本発明の薬剤組成物は、細菌を死滅もしく
は阻害するのとはおそらく別のメカニズムによって細菌
活性を制御することができる。かくして、熱傷の治療に
おける第二の問題が解決される。大量の抗生物質の投与
は不要となり、傷組織の修正と再生とに資することがで
きる。本発明の薬剤組成物は、創傷部の進行性壊死を軽
減することができる。本発明の薬剤で処理することによ
って、湿った状態を保つことができ、皮膚の再生に好条
件が醸成され、薬物の作用は治癒を促進する。それ故、
深い二度熱傷さえ、傷跡を残さずに治癒することがで
き、そして、広い面積に及ぶ熱傷も十分に治療すること
ができる。[0011] The pharmaceutical compositions of the present invention can control bacterial activity through a mechanism likely to kill or inhibit bacteria. Thus, the second problem in treating burns is solved. The administration of a large amount of antibiotics is not required, which can contribute to repair and regeneration of wound tissue. The pharmaceutical composition of the present invention can reduce progressive necrosis of a wound. By treatment with the agent of the present invention, a moist state can be maintained, favorable conditions for skin regeneration are created, and the action of the drug promotes healing. Therefore,
Even deep double burns can heal without leaving scars, and large area burns can be treated well.
【００１２】本発明の効果を、図面を参照しつつ、より
詳細に説明する。前述のごとく、本発明の薬剤組成物
は、ヒトおよびその他の温血動物の創傷、疾病等の治療
に用いられるが、最も適したものは、熱傷の治療に用い
ることである。本発明の薬剤は、３〜１５重量％のミツ
ロウと、８５〜９７重量％の中薬のゴマ油抽出物とから
なる。ここに％は、本発明の薬剤組成物の全重量に対す
る割合を示す。ゴマ油抽出物は黄苓、黄蓮、黄柏、地龍
および罌粟穀からなる中薬の成分を含んでいる。各中薬
原料のゴマ油に対する量は、乾物として２〜１０重量％
である。 本発明の薬剤組成物の有効成分本体について
は、未だ明らかでないが、β−シトステロールが有効成
分の一つであることが確認されている。β−シトステロ
ールは、周知のとおり、動植物中に広く分布しており、
その化学名はスティグマスト−５−エン−３−オールで
ある。分子式はＣ２９Ｈ５０，Ｏ分子量は４１４．６
９、融点は１４０℃である。コレステロールを投与した
チンパンジーにβ−シトステロールを投与すると血中の
脂質濃度が低下することが知られている。また、β−シ
トステロールのジオキシドは、β−シトステロール自体
よりその効果が大きいことも知られている。（ケミカル
・アブストラクツ８８：２１０７１ｆ，１９７８および
同８６：４１８ｈ，１９７８参照）。The effects of the present invention will be described in more detail with reference to the drawings. As mentioned above, the pharmaceutical composition of the present invention is used for treating wounds, diseases and the like of humans and other warm-blooded animals, and the most suitable one is used for treating burns. The medicament of the present invention consists of 3 to 15% by weight of beeswax and 85 to 97% by weight of Chinese medicinal sesame oil extract. Here,% indicates the ratio to the total weight of the pharmaceutical composition of the present invention. The sesame oil extract contains components of Chinese medicine consisting of Huangling, Huangren, Huangbashi, Jilong and poppy. The amount of each Chinese medicine raw material to sesame oil is 2 to 10% by weight as dry matter.
It is. Although it is not yet clear about the active ingredient itself of the pharmaceutical composition of the present invention, it has been confirmed that β-sitosterol is one of the active ingredients. As is well known, β-sitosterol is widely distributed in animals and plants,
Its chemical name is stigmast-5-en-3-ol. The molecular formula is C 29 H 50 , and the O molecular weight is 414.6.
9. The melting point is 140 ° C. It is known that administration of β-sitosterol to chimpanzees to which cholesterol has been administered decreases blood lipid levels. It is also known that β-sitosterol dioxide is more effective than β-sitosterol itself. (See Chemical Abstracts 88: 21071f, 1978 and 86: 418h, 1978).
【００１３】β−シトステロールは、エスシンと配合し
て局所消炎剤として使用される。エスシンＮａ塩とβ−
シトステロールの複合体を０．２ｍｇ注射すると、何ら
刺激反応を生ぜず、カラゲーニン誘発浮腫をラットで１
３．５％抑制した。一方、エスシン単独では、０．１ｍ
ｇ注射により刺激反応を生じ、浮腫は１８．６％増加し
た。エスシンの毒性はβ−シトステロールにより低下す
ることが知られている（ケミカル・アブストラクツ、８
６：１６１２９８ｕ，１９７７）。しかしながらβ−シ
トステロールを熱傷の治療に用いることは文献上知られ
ていない。本発明の薬剤組成物中のβ−シトステロール
含量は０．２重量％またはそれ以上である。本発明の薬
剤組成物の原料は動物および植物である。これら原料は
予熱したゴマ油中に加えられる。この過程において、お
そらくは、β−シトステロールはゴマ油中の長鎖脂肪酸
と縮合してエステルを形成する。このエステル類が傷の
浸出物と反応して緩やかにケン化して、β−シトステロ
ールを遊離し、この過程でβ−シトステロールの創傷組
織に対する作用が助長されるのではないかと推測され
る。ミツロウは軟膏基材であると同時に、抗酸化、抗酸
性化作用による保存剤としても働き、またそのエッセン
スは皮膚保護作用を有する。本発明の薬剤組成物の各成
分が治療効果を有し、それらが相まって相乗的に熱傷治
療効果を示すものとおもわれる。Β-sitosterol is used as a local anti-inflammatory agent in combination with escin. Escin Na salt and β-
Injection of 0.2 mg of the complex of sitosterol did not produce any stimulatory response and caused carrageenin-induced edema in rats by 1 mg / ml.
3.5% was suppressed. On the other hand, escin alone is 0.1m
The g injection produced a irritant response, with edema increasing by 18.6%. It is known that the toxicity of escin is reduced by β-sitosterol (Chemical Abstracts, 8
6: 161298u, 1977). However, the use of β-sitosterol for treating burns is not known in the literature. The β-sitosterol content in the pharmaceutical composition of the present invention is 0.2% by weight or more. The raw materials of the pharmaceutical composition of the present invention are animals and plants. These ingredients are added to preheated sesame oil. In this process, β-sitosterol probably condenses with long chain fatty acids in sesame oil to form esters. It is presumed that these esters react with wound exudate and gently saponify to release β-sitosterol, and in this process the action of β-sitosterol on wound tissue may be promoted. Beeswax is an ointment base, and at the same time, acts as a preservative due to its antioxidant and antiacidifying effects, and its essence has a skin protecting effect. It is considered that each component of the pharmaceutical composition of the present invention has a therapeutic effect, and when combined, synergistically exhibits a burn treating effect.
【００１４】[0014]
【実施例】次に、本発明を実施例と試験例とによって、
より詳細に説明する。 実施例１ 図１のフローチャートで示すとおり、中華人民共和国局
方の品質規格を満たす黄苓２ｋｇ、黄蓮２ｋｇおよび黄
柏２ｋｇをそれぞれ細片とし、これに地龍２ｋｇおよび
罌粟穀２ｋｇを混合した。抽出釜に市販ゴマ油１００ｋ
ｇを入れて１２０℃に加熱した。これに、前記の混合物
を加え、１２０℃で４５分間攪拌した。放冷後、濾過し
て残渣を捨て、抽出物を放置し、ついで、透明油状物と
して取り出した。かくして、本発明の薬剤成分のうち、
ゴマ油抽出物を得た。この抽出物８５ｋｇをとり、市販
ミツロウ１５ｋｇと十分に混合して、本発明の薬剤組成
物を得た。Next, the present invention will be described based on Examples and Test Examples.
This will be described in more detail. Example 1 As shown in the flow chart of FIG. 1, 2 kg of Huangling, 2 kg of Huangren and 2 kg of Huangbai, which meet the quality standards of the People's Republic of China, were made into small pieces, and 2 kg of ground dragon and 2 kg of poppy grains were mixed. Commercial sesame oil 100k in the extraction pot
g and heated to 120 ° C. The above mixture was added thereto, and the mixture was stirred at 120 ° C. for 45 minutes. After cooling, the mixture was filtered, the residue was discarded, the extract was allowed to stand, and then taken out as a clear oil. Thus, among the drug components of the present invention,
A sesame oil extract was obtained. 85 kg of this extract was taken and thoroughly mixed with 15 kg of commercially available beeswax to obtain the pharmaceutical composition of the present invention.
【００１５】実施例２ 黄苓１ｋｇ、黄蓮１ｋｇおよび黄柏１ｋｇを細片とし、
これに地龍１ｋｇおよび罌粟穀１ｋｇを加えて十分に混
合した。市販ゴマ油１０ｋｇを１８０℃に加熱し、これ
に前記の混合物を加え、１８０℃で３０分間保った。こ
のゴマ油抽出液９．７ｋｇに、１８０℃に予熱したミツ
ロウ０．３ｋｇを加えて混合し、本発明の薬剤組成物を
得た。Example 2 1 kg of Huangling, 1 kg of Huangren and 1 kg of Huangbashi are made into strips.
1 kg of ground dragon and 1 kg of poppy were added to this and mixed well. 10 kg of commercially available sesame oil was heated to 180 ° C., and the mixture was added thereto and kept at 180 ° C. for 30 minutes. 0.3 kg of beeswax preheated to 180 ° C. was added to 9.7 kg of this sesame oil extract and mixed to obtain a pharmaceutical composition of the present invention.
【００１６】実施例３ １００℃に予熱したミツロウを使用した以外は、実施例
１の方法に従ってゴマ油抽出物と混合して本発明の薬剤
組成物を得た。 試験例１ 組織学的試験 熱傷の程度を次のとおり規定した。 一度：表皮のみの熱傷 二度：真皮に及ぶ熱傷 三度：皮膚全層の熱傷 Ａ．体重２〜２．５ｋｇの雌雄各７頭のウサギの腰骨部
分を脱毛し、１ｃｍ２の面積に深い二度熱傷をつけた。
ウサギは無作為に２群に分け、対照区は乾式治療法を、
そして本発明の試験区は実施例１に記載の薬剤組成物の
処理をした゜ １８日後に、光学顕微鏡で熱傷組織を検査した。その結
果、図２のとおり対照区のウサギの組織は、顆粒組織の
萎縮、分葉球の浸出を認め、そして好酸球膠原質線維と
顆粒組織は壊死してい。一方、本発明の試験区の動物の
組織は図３のとおり、顕微鏡下で線維芽細胞の活発な増
殖、血管の発育、顆粒組織の完全な生育が認められた。 Ｂ．体重１００〜１２０ｇの純系ウィスター・ラット１
２０頭の背中を脱毛し、脱毛部分の約２０％に三度の熱
傷をつけた。患部全体に４×１０８菌量の黄色ブドウ状
球菌の懸濁液を塗布し、各動物を４群に分け、表１に示
すそれぞれ異なる治療法に付した。Example 3 A pharmaceutical composition of the present invention was obtained by mixing with a sesame oil extract according to the method of Example 1 except that beeswax preheated to 100 ° C. was used. Test Example 1 Histological Test The degree of burn was defined as follows. Once: burns only on the epidermis Twice: burns on the dermis Third: burns on all layers of the skin The hip bones of seven male and female rabbits each weighing 2 to 2.5 kg were depilated and deeply burned twice to an area of 1 cm 2 .
Rabbits were randomly divided into two groups, control group received dry treatment,
In the test plot of the present invention, the burn tissue was examined by an optical microscope 18 days after the treatment with the drug composition described in Example 1. As a result, as shown in FIG. 2, in the tissues of the rabbits in the control group, atrophy of granule tissue and exudation of lobules were observed, and eosinophil collagen fibers and granule tissue were necrotic. On the other hand, in the tissues of the animals in the test plot of the present invention, as shown in FIG. 3, active proliferation of fibroblasts, development of blood vessels, and complete growth of granular tissue were observed under a microscope. B. Pure Wistar rat 1 weighing 100-120 g
Twenty backs were depilated and about 20% of the depilated area was burned three times. A suspension of Staphylococcus aureus in an amount of 4 × 10 8 cells was applied to the entire affected area, and each animal was divided into four groups and subjected to different treatments shown in Table 1.
【００１７】[0017]
【表１】 [Table 1]
【００１８】各動物を１日目、３日目、５日目、７日目
および９日目に殺し、熱傷部分の深部組織を切りとり、
無菌操作により、４群の細菌数測定を行った。各群の菌
数を平均対数値で比較した。その結果、表２に示すとお
り、本発明の薬物またはＳＤ−Ａｇにより処理した動物
群は乾熱暴露治療法および対照区の動物群とくらべて顕
著に少ない細菌数を示した（Ｐ＜０．０１）。一方、乾
熱暴露治療法区および対照区の間では有意差は認められ
なかった。（Ｐ＞０．０５）。本発明の薬物の治療区と
ＳＤ−Ａｇ治療区との間には有意の差は認められなかっ
た（Ｐ＞０．０５）。Each animal was killed on days 1, 3, 5, 7, and 9 and the deep tissue of the burn was cut off.
The bacteria count of four groups was measured by aseptic operation. The number of bacteria in each group was compared by the mean logarithm. As a result, as shown in Table 2, the group of animals treated with the drug of the present invention or SD-Ag showed a significantly smaller number of bacteria than the group of animals in the dry heat exposure treatment method and the control group (P <0. 01). On the other hand, no significant difference was observed between the dry heat exposure treatment group and the control group. (P> 0.05). No significant difference was observed between the group treated with the drug of the present invention and the group treated with SD-Ag (P> 0.05).
【００１９】[0019]
【表２】 各区の組織の細菌数の経時的変化は図４に示すとおりで
ある。[Table 2] The time-dependent change in the bacterial count of the tissue in each section is as shown in FIG.
【００２０】試験例２ 病理学的試験 三度熱傷を受け皮膚移植したのち長期間放置された患者
に、本発明の実施例２の薬物を処理し、処理前後の状態
を光学顕微鏡および電子顕微鏡で観察した。光学顕微鏡
による観察は２００倍で行った。治療開始前は図５およ
び図６に示すとおり、汗腺および毛のう近辺に炎症細胞
および病変損傷が認められた。これに対して、治療後
は、図７に示すとおり、損傷皮膚が正常に治癒し、真皮
層に毛細血管と線維芽細胞の新生が認められた。一方、
電子顕微鏡による観察は、治療開始前は図８および図９
は１００００倍、図１０は８０００倍でそれぞれ示すと
おりであり、細胞核の周辺には多数の球状空胞が認めら
れ、そして核の表面は不規則状であった。内胚葉は消失
し、真皮層の可撓性線維の厚さは不均一であり、かつ線
維の配列は無秩序状態であった。また、細胞の沈着が認
められた。治療後は、図１１は４０００倍、図１２は６
０００倍、図１３は５０００倍でそれぞれ示すとおりで
あり、とげ状細胞層の細胞は規則正しく正常に配列して
いることが認められる。細胞核は原内胚葉を伴って明瞭
に認めることができる。核のクロスチン分布は均一であ
り、橋小体が正常に復帰していることも認められる。Test Example 2 Pathological Test Patients who had undergone three burns and were left for a long period after skin transplantation were treated with the drug of Example 2 of the present invention, and the state before and after the treatment was observed with an optical microscope and an electron microscope. Observed. Observation with an optical microscope was performed at a magnification of 200 times. Before the start of the treatment, as shown in FIGS. 5 and 6, inflammatory cells and lesion damage were observed near the sweat glands and hair follicles. On the other hand, after the treatment, as shown in FIG. 7, the damaged skin was normally healed, and the formation of capillaries and fibroblasts was observed in the dermis layer. on the other hand,
Observation with an electron microscope is shown in FIGS.
As shown in FIG. 10 at 10,000 times and FIG. 10 at 8000 times, many spherical vacuoles were observed around the cell nucleus, and the surface of the nucleus was irregular. The endoderm disappeared, the thickness of the flexible fibers in the dermis layer was uneven, and the arrangement of the fibers was disordered. In addition, cell deposition was observed. After treatment, FIG. 11 is 4000 times and FIG.
The results are shown at 000-fold and FIG. 13 at 5,000-fold, respectively, and it is confirmed that the cells in the spiny cell layer are regularly arranged normally. Cell nuclei can be clearly seen with protoderm. The distribution of nucleus clostin is uniform, and it is also observed that the pontine corpuscle has returned to normal.
【００２１】試験例３ 薬物動力学的試験（抗感染症試
験） Ａ．モルモット７頭の背部両面を脱毛し、脱毛部位を熱
傷させた。２日後に、熱傷処理部位の両方ともに、試験
例１Ｂと同様にして黄色ブドウ状球菌の懸濁液を塗布
し、その一方部位のみを塗布後６時間目に本発明の実施
例３の薬剤で処理をした。他方部位には何らの処理をも
しなかった。その結果、無処理部位では、菌の著しい侵
入が認められたが、処理部位では感染が認められなかっ
た。モルモット２８頭を用いて４回、試験を繰り返した
が、結果はいずれも同じであった。 Ｂ．モルモット２８頭を無作為に４群に分け、１群７頭
の全てを上記Ａのように脱毛し、熱傷処理をした。熱傷
処理の一方部位は自然治癒させ（対照区）、他方部位は
本発明の薬剤で処理をした（処理区）。モルモットを熱
傷処理後３日目、６日目、１０日目および２０日目に殺
し、熱傷処理した部位の内奥側の組織の菌数を測定し
た。その結果を表３に示す。Test Example 3 Pharmacokinetic Test (Anti-Infectious Disease Test) Hair was removed on both sides of the back of seven guinea pigs, and the hair loss site was burned. Two days later, a suspension of Staphylococcus aureus was applied to both the burn-treated sites in the same manner as in Test Example 1B, and only one of the sites was treated with the drug of Example 3 of the present invention 6 hours after application. Processed. The other site was not treated at all. As a result, significant invasion of bacteria was observed at the untreated site, but no infection was observed at the treated site. The test was repeated four times using 28 guinea pigs, and the results were all the same. B. Twenty-eight guinea pigs were randomly divided into four groups, and all of the seven guinea pigs were depilated as described in A above and burned. One part of the burn treatment was allowed to heal spontaneously (control), and the other part was treated with the agent of the present invention (treatment). Guinea pigs were killed on the third, sixth, tenth, and twenty days after the burn treatment, and the number of bacteria in the tissue deep inside the burn-treated site was measured. Table 3 shows the results.
【００２２】[0022]
【表３】 [Table 3]
【００２３】試験例４ 薬物動力学的試験（汗腺の上皮
再生試験） 見かけ上三度熱傷を同程度有する患者を対象として試験
をした。熱傷部位の半分をヒトの羊膜でおおい、一方、
残り半分を本発明の実施例２の薬剤で処理した。その
後、光学顕微鏡で皮膚の病理学的所見を検査した。図１
４はヒト羊膜でおおった熱傷部位であるが、傷部位は２
層ないし３層の上皮細胞で覆われている。熱傷部位の内
部は真皮表面部分に浮腫が発生している。膠原繊維は破
壊され、皮膚付属器は認められない。図１５は本発明の
薬剤で処理された熱傷部位であるが、上皮層は完全に回
復している。上皮層の細胞は順序正しく配列し、新しい
上皮形成がみられる。真皮組織中には汗腺の残存が認め
られる。Test Example 4 Pharmacokinetic Test (Test for Regeneration of Epithelium of Sweat Gland) A test was conducted on patients having apparently the same degree of third-degree burns. Half of the burn site is covered with human amniotic membrane,
The other half was treated with the drug of Example 2 of the present invention. The skin was then examined for pathological findings with a light microscope. FIG.
Reference numeral 4 denotes a burn site covered with human amniotic membrane, but the wound site is 2
It is covered with three to three layers of epithelial cells. Edema has occurred on the surface of the dermis inside the burn site. Collagen fibers are destroyed and no skin appendages are observed. FIG. 15 shows a burn site treated with the agent of the present invention, in which the epithelial layer has completely recovered. The cells in the epithelial layer are ordered and new epithelium is formed. Sweat glands remain in the dermal tissue.
【００２４】試験例５ 薬物動力学的試験（創傷治癒試
験） モルモット２１頭を１群７頭の３群に分け、各動物の背
部両面を脱毛し、脱毛部位に直径２ｃｍの深い二度熱傷
を生じさせた。熱傷部位の一方は、本発明の実施例２の
薬剤で処理し、他方、残り半分はＳＤ−Ａｇ、アナグマ
脂またはゴマ油とミツロウ混合物（９７：３）で処理し
て、各々対照区とした。損傷の大きさを経時的に測定
し、処理後の治癒時間を記録した。治癒率を次式で算出
した。Test Example 5 Pharmacokinetic Test (Wound Healing Test) Twenty-one guinea pigs were divided into three groups, seven in one group, and the back of each animal was depilated on both sides. Spawned. One of the burn sites was treated with the agent of Example 2 of the present invention, while the other half was treated with SD-Ag, badger oil or sesame oil and beeswax mixture (97: 3), each serving as a control. The size of the lesion was measured over time and the healing time after treatment was recorded. The cure rate was calculated by the following equation.
【００２５】[0025]
【数１】 その結果を表４に示す。(Equation 1) Table 4 shows the results.
【００２６】[0026]
【表４】 [Table 4]
【００２７】表４から明らかなとおり、本発明の薬剤処
理を行ったときは、対照の薬剤処理を行った場合にくら
べてより速やかに傷治癒が達成された。最大損傷率が体
表面積の２０％を占める場合を含めて、５０人の熱傷患
者を本発明の薬剤で処理した。一方、最大損傷率が体表
面積の１０％を占める２０人の患者を通常の暴露治療法
で治療した。両群間で、鎮痛作用、治癒時間、感染率、
毒物反応、治療の経過、創傷部位の感覚のとりもどし等
で、治療効果を比較した。その結果、発明の薬剤は良好
な鎮痛および抗感染効果を示すことがわかった。また、
傷治療が促進され、薬物による副作用を認めなかった。
また、頸部びらんを有する２００人の患者を本発明の薬
剤で処理したところ、顕著な治療効果が認められた。As is clear from Table 4, when the drug treatment of the present invention was performed, wound healing was achieved more quickly than when the control drug treatment was performed. Fifty burn patients were treated with the agents of the present invention, including cases where the maximum injury rate occupied 20% of the body surface area. On the other hand, 20 patients with a maximum injury rate occupying 10% of the body surface area were treated with conventional exposure therapy. Analgesia, healing time, infection rate,
The therapeutic effects were compared in terms of toxic reactions, progress of treatment, restoring the wound site, and the like. As a result, it was found that the drug of the present invention exhibited good analgesic and anti-infective effects. Also,
Wound healing was accelerated and there were no drug side effects.
When 200 patients with cervical erosion were treated with the drug of the present invention, a remarkable therapeutic effect was observed.
【００２８】さらに、潰瘍面積が最大６％であり、骨膜
まで達するものを含む。種々の程度の潰瘍患者であっ
て、最長６ヶ月、最短４ヶ月の病歴の者に本発明の薬剤
を一日４回局所投与したところ、１５ないし２０日で潰
瘍は治癒した。Further, the ulcer area is up to 6%, including those reaching the periosteum. The topical administration of the agent of the present invention four times a day to patients with various degrees of ulcer, who had a history of up to 6 months and a minimum of 4 months, healed in 15 to 20 days.
【発明の効果】本発明の外用剤は、熱傷等の傷、痔疾等
に局所的に塗布することにより、鎮痛、静菌作用を示
し、熱傷等を完治させることができる。The topical preparation of the present invention shows an analgesic and bacteriostatic action when applied topically to wounds such as burns, hemorrhoids and the like, and can completely cure burns and the like.
【図面の簡単な説明】[Brief description of the drawings]
【図１】本発明の薬剤組成物を製造する方法のフローシ
ートである。FIG. 1 is a flow sheet of a method for producing a pharmaceutical composition of the present invention.
【図２】ウサギによる試験例１における深い二度熱傷を
１８日間乾式治療法で処置した熱傷皮膚組織の形態の４
００倍の光学顕微鏡写真である。FIG. 2 shows the morphology of burned skin tissue obtained by treating a deep double burn in rabbits with dry treatment for 18 days in Test Example 1.
It is an optical microscope photograph of 00 times.
【図３】ウサギによる試験例１における深い二度熱傷を
本発明の薬剤組成物で局所的に処置したときの処置１８
日目の熱傷皮膚組織の形態４００倍の光学顕微鏡写真で
ある。FIG. 3 shows a treatment 18 in which a deep double burn in Test Example 1 by a rabbit was topically treated with the pharmaceutical composition of the present invention.
It is the optical microscope photograph of the form of the burn skin tissue of the day 400 times.
【図４】各組織における細菌数を経時的に示したグラフ
である。FIG. 4 is a graph showing the number of bacteria in each tissue over time.
【図５】三度熱傷を負ったヒトの皮膚の治療開始前の形
態の４００倍の光学顕微鏡写真である。FIG. 5 is a 400 × light micrograph of the morphology of a human skin with three burns before treatment is started.
【図６】三度熱傷を負ったヒトの皮膚の治療開始前の形
態の４００倍の光学顕微鏡写真である。FIG. 6 is a 400 × optical micrograph of a morphology of a human skin with three burns before treatment is started.
【図７】第７図は、三度熱傷を負ったヒトの皮膚を、本
発明の薬剤組成物で処理したときの処理後の熱傷皮膚の
形態の光学顕微鏡写真である。FIG. 7 is an optical micrograph of the morphology of burned skin after treatment of a human skin that has been burned three times with the pharmaceutical composition of the present invention.
【図８】三度熱傷を負ったヒトの皮膚の治療開始前の形
態の電子顕微鏡写真である。FIG. 8 is an electron micrograph of the morphology of a human skin that has suffered a third burn before starting treatment.
【図９】三度熱傷を負ったヒトの皮膚の治療開始前の形
態の電子顕微鏡写真である。FIG. 9 is an electron micrograph of the morphology of a human skin with three burns before treatment is started.
【図１０】三度熱傷を負ったヒトの皮膚の治療開始前の
形態の電子顕微鏡写真である。FIG. 10 is an electron micrograph of the morphology of a human skin that has suffered three burns before treatment is started.
【図１１】三度熱傷を負ったヒトの皮膚の本薬剤による
治療開始後の形態の電子顕微鏡写真である。FIG. 11 is an electron micrograph of the morphology of human skin with three burns after treatment with the present drug is started.
【図１２】三度熱傷を負ったヒトの皮膚の本薬剤による
治療開始後の形態の電子顕微鏡写真である。FIG. 12 is an electron micrograph of the morphology of human skin with three burns after the start of treatment with the present drug.
【図１３】三度熱傷を負ったヒト皮膚の本薬剤による治
療開始後の形態の電子顕微鏡写真である。FIG. 13 is an electron micrograph of the morphology of human skin injured three times after treatment with the present drug is started.
【図１４】浅い三度熱傷を負った患者を半膜で覆った皮
膚の病理学的断面の形態の光学顕微鏡写真である。FIG. 14 is an optical micrograph of the morphology of a pathological cross section of skin covered with a semi-membrane in a patient who has suffered a shallow third burn.
【図１５】試験例２における浅い三度熱傷患者を本発明
の薬剤組成物で処理したときの皮膚の形態の病理学的断
面の光学顕微鏡写真である。FIG. 15 is an optical micrograph of a pathological section of skin morphology when a shallow third-degree burn patient in Test Example 2 was treated with the pharmaceutical composition of the present invention.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ // Ａ６１Ｋ 31/575 Ａ６１Ｋ 31/575 (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 35/78 A61K 35/56 A61P 17/02 A61K 31/575 ＢＩＯＳＩＳ（ＤＩＡＬＯＧ) ＣＡ（ＳＴＮ)────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 7 identification code FI // A61K 31/575 A61K 31/575 (58) Investigated field (Int.Cl. 7 , DB name) A61K 35/78 A61K 35 / 56 A61P 17/02 A61K 31/575 BIOSIS (DIALOG) CA (STN)
Claims (19)
ツロウと、（２）全量の８５〜９７重量部を占めるゴマ
油抽出物からなり、各該抽出物は原料乾物として重量の
２〜１０重量部を占め、そして該抽出物が黄苓、黄蓮、
黄柏、地龍および罌粟穀であることを特徴とする、ヒト
を含む温血動物の熱傷治療剤。(1) Beeswax occupying 3 to 15 parts by weight of the total amount; and (2) Sesame oil extract occupying 85 to 97 parts by weight of the total amount. Occupies 10 parts by weight, and the extract contains yellowing, yellow lotus,
A therapeutic agent for burns of warm-blooded animals including humans, which is characterized by Huangkashi, Chiryu and poppy.
量部以上含有する請求項１に記載の熱傷治療剤。2. The burn remedy according to claim 1, which comprises 0.20 parts by weight or more of β-sitosterol in total amount.
る、Ｓｃｕｔｅｌｌａｒｉａ ｂａｉｃａｌｅｎｓｉａ
Ｇｅｏｒｇｉ，Ｓ．ｖｉｓｃｉｄｕｌａ Ｂｇｅ．，
Ｓ．ａｍｏｅｎａ Ｃ．Ｈ．Ｗｒｉｇｈｔ，Ｓ．ｒｅｈ
ｄｅｒｉａｒａＤｉｅｌｓ，Ｓ．ｉｋｏｎｎｉｋｏｖｉ
ｉ Ｊｕｚ．，Ｓ．ｌｉｋｉａｎｇｅｎｓｉｓ Ｄｉｅ
ｌｓおよびＳ．ｈｙｐｅｒｉｃｉｆｏｌｉａ Ｌｅｖｌ
から選ばれる植物体の一部である、請求項１に記載の熱
傷治療剤。3. Scutellaria baicalensia, wherein Huangling belongs to the Labialal family.
Georgi, S.M. viscidula Bge. ,
S. amoena C.A. H. Wright, S.M. reh
DeliaraDiels, S.M. ikonnikovi
i Juz. , S .; likiangensis Die
ls and S.L. hypericifolia Levl
The agent for treating burns according to claim 1, which is a part of a plant selected from the group consisting of:
科に属する、Ｃｏｐｔｉｓ ｃｈｉｎｅｎｓｉｓ Ｆ
ｒａｎｃｈ，Ｃ．ｄｅｌｔｏｉｄｅａ Ｃ．Ｙ．ｅｔ
Ｈｓｉａｏ，Ｃ．ａｍｅｉｅｎｓｉｓ（ｃｈｅｎ）Ｃ．
Ｙ．ＣｈｅｎｇおよびＣ．ｔｅｅｔｏｉｄｅｓ Ｃ．
Ｙ．Ｃｈｅｎｇから選ばれる植物体の一部である、請求
項１に記載の熱傷治療剤。4. The yellow lotus is Ranunc-ulaceae.
Coptis chinensis F belonging to the family
ranch, C .; deltoidea C.I. Y. et
Hsiao, C.I. ameensis (chen) C.I.
Y. Cheng and C.I. teetoides C.I.
Y. The agent for treating burns according to claim 1, which is a part of a plant selected from Cheng.
Ｐｈｅｌｌｏｄｅｎｄｒｏｎ ａｍｕｒｅｎｓ Ｒｕｐ
ｒ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ，Ｐ．ｃｈ
ｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ，ｖａｒ．ｆａｌｃｕｔ
ｕｍ Ｈｕａｎｇ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｉｎ
ｅｉｄ ｖａｒ．ｓｌａｂｒｉｕｓｃｕｌｕｍ Ｓｃｈ
ｎｅｉｄ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ ｖ
ａｒ．ｏｍｅｉｅｎｓｅ ＨｕａｎｇおよびＰ．ｃｈｉ
ｎｅｎｓｅ Ｓｃｈｎｅｉｄｖａｒ．ｙｕｎｎａｎｅｎ
ｓｅ Ｈｕａｎｇから選ばれる植物体の一部である、請
求項１に記載の熱傷治療剤。5. Huangkashia belongs to the family Rutaceae,
Phellodendronic amurens Rup
r, P. chinense Schneid, P .; ch
inense Schneid, var. falcut
um Huang, P .; chinense Schin
eid var. slabrusculum Sch
neid, P .; chinense Schneid v
ar. omeiense Huang and P.M. chi
nense Schneidvar. yunnanen
The agent for treating burns according to claim 1, which is a part of a plant selected from se Huang.
ｇｉｌｌｕｍ（Ｅ．Ｐｅｒｒｉｅｒ）およびＡｌｌｏｌ
ｏｂｏｐｈｏｒａ ｃａｌｉｇｉｎｏｓａｔｒａｐｅｚ
ｏｉｄｅｓ（Ａｎｔ．Ｄｉｇｅｓ）から選ばれる、請求
項１に記載の熱傷治療剤。6. The land dragon is Pheretina asper
gillum (E. Perrier) and Allol
obobophora caliginosatrapez
The agent for treating burns according to claim 1, which is selected from oides (Ant. Diges).
ある、請求項１に記載の熱傷治療剤。7. The agent for treating burns according to claim 1, wherein the ground dragon is dried or raw whole ground dragon.
き、一方では地龍および罌粟穀を精選し、（２）ゴマ油
を１２０℃ないし１８０℃に予熱し、（３）黄苓、黄蓮
および黄柏の細片および地龍、罌粟穀を、それらの全量
とゴマ油との比が各２〜１０対１００になるように加え
て混合し、ついで全体を３０〜４５分間沸とうさせ、
（４）放冷後、残渣を捨てて、黄苓、黄蓮、黄柏、地龍
および罌粟穀の有効成分を含有するゴマ油抽出物を得、
（５）該ゴマ油抽出物８５〜９７重量部と３〜１５重量
部のミツロウとを混合することを特徴とする請求項１に
記載の熱傷治療剤の製造方法。8. (1) Finely crush yellowling, yellow lotus and yellow crocodile, while carefully selecting ground dragon and poppy, (2) preheating sesame oil to 120 ° C to 180 ° C, (3) yellowing, The yellow lotus and the yellow leaves, the ground dragon, and the poppy grains were added and mixed so that the ratio of the whole amount to sesame oil was 2 to 10 to 100, respectively, and then the whole was boiled for 30 to 45 minutes,
(4) After standing to cool, the residue is discarded, and a sesame oil extract containing active ingredients of Huangling, Huangli, Huangbai, Jilong and poppy is obtained,
(5) The method for producing a burn treatment agent according to claim 1, wherein 85 to 97 parts by weight of the sesame oil extract and 3 to 15 parts by weight of beeswax are mixed.
ｃｕｔｅｌｌａｒｉａ ｐａｉｃａｌｅｎｓｉｓ Ｇｅ
ｏｒｇｉ，Ｓ．ｖｉｓｃｉｄｕｌａ Ｂｇｅ．，Ｓ．ａ
ｍｏｅｎａ Ｃ．Ｈ．Ｗｒｉｇｈｔ，Ｓ．ｒｅｈｄｅｒ
ｉａｎａ Ｄｉｅｌｓ，Ｓ．ｉｋｏｎｎｏｒｋｏｖｉｉ
Ｊｕｚ，Ｓ．ｌｉｋｉａｎｇｅｎｓｉｓ Ｄｉｅｌｓ
およびＳ．ｈｙｐｅｒｉｃｉｆｏｌｉａ Ｌｅｖｅｌか
ら選ばれる植物の部分である請求項８に記載の方法。9. The huangling is an S belonging to the Labiatae family.
cutellaria pacalensis Ge
orgi, S .; viscidula Bge. , S .; a
moena C.I. H. Wright, S.M. rehder
Iana Diels, S.M. ikonnorkovii
Juz, S .; likeiangensis Diels
And S.I. The method according to claim 8, which is a part of a plant selected from hypericifolia Level.
科に属するＣｏｐｔｉｓ ｃｈｉｎｅｎｓｉｓ Ｆｒａ
ｎｃｈ，Ｃ．ｄｅｌｔｏｉｄｅａ Ｃ．Ｙ．Ｃｈｅｎｇ
ｅｔ Ｈｓｉａｏ，Ｃ．ｏｍｅｉｅｎｓｉｓ（Ｃｈｅ
ｎ）Ｃ．Ｙ．ＣｈｅｎｇおよびＣ．ｔｅｅｔｏｉｄｅｓ
Ｃ．Ｙ．Ｃｈｅｎｇから選ばれる植物の部分である請
求項８に記載の方法。10. The yellow lotus is Ranunculaceal.
Coptis chinensis Fra
nch, C.I. deltoidea C.I. Y. Cheng
et Hsiao, C.I. omeiensis (Che
n) C.I. Y. Cheng and C.I. teetoides
C. Y. 9. The method according to claim 8, which is a plant part selected from Cheng.
Ｐｈｅｌｌｏｄｅｎｄｒｏｎ ａｍｕｒｅｎｓｅ Ｐｕ
ｐｒ．Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｎｅｉｄ，Ｐ．Ｓ
ｃｈｎｅｉｄ ｖａｒ．ｆａｌｃｕｔｕｍ Ｈｕａｎ
ｇ，Ｐ．ｃｈｉｎｅｎｓｅ Ｓｃｈｉｎｅｉｄ ｖａ
ｒ．ｇｌａｂｒｉｕｓｃｕｌｕｍ Ｓｃｈｉｎｅｉｄ．
Ｐ．ｃｈｉｎｅｎｓｅ ｓｃｈｉｎｅｉｄ ｖａｒ．ｏ
ｍｅｉｅｎｓｅ ＨｕａｎｇおよびＰ．ｃｈｉｎｅｎｓ
ｅ Ｓｃｈｎｅｉｄ ｖａｒ．ｙｕｎｎａｎｅｎｓｅ
Ｈｕａｎｇから選ばれる植物の部分である請求項８に記
載の方法。11. Huangkashia is a Phlendendron amurense Pu belonging to the family Rutaceae.
pr. P. chinense Schneid, P .; S
chneid var. falcutum Huan
g, P. Chinese Sineid va
r. glabrisculum Scheinid.
P. chinense scheinid var. o
meiense Huang and P.M. chinens
e Schneid var. yunnanense
9. The method according to claim 8, which is a plant part selected from Huang.
ｅｒｇｉｌｌｕｍ（Ｅ．Ｐｅｒｒｉｅｒ）およびＡｌｌ
ｏｌｏｂｏｐｈｏｒａ ｃａｌｉｇｉｎｏｓａ ｔｒａ
ｐｅｚｏｉｄｅｓ（Ａｎｔ．Ｄｕｇｅｓ）から選ばれる
請求項８に記載の方法。12. The land dragon is a Phetima asp.
ergillum (E. Perrier) and All
olobophora caliginosa tra
9. The method according to claim 8, wherein the method is selected from pezoides (Ant. Duges).
ある請求項８または請求項１２に記載の方法。13. The method according to claim 8, wherein the ground dragon is whole dried or raw earthworms.
０，０００部の水分を含有する請求項８に記載の方法。14. The sesame oil is 1/1000 to 1/1.
9. The method according to claim 8, containing 000 parts of water.
ラフィン含有量である請求項８に記載の方法。15. The method according to claim 8, wherein the beeswax has a paraffin content of less than 20% by weight.
ツロウを１２０℃ないし１８０℃に予熱する請求項８に
記載の方法。16. The method according to claim 8, wherein the beeswax is preheated to 120 ° C. to 180 ° C. prior to mixing with the sesame oil extract.
それ以上のβ−シトステロールを含有する請求項８に記
載の方法。17. The method according to claim 8, which comprises 0.2% by weight or more of β-sitosterol based on the total amount of the pharmaceutical composition.
ヒトおよび他の温血動物の熱傷治療用薬剤組成物。18. Produced by the method of claim 8,
Pharmaceutical compositions for treating burns in humans and other warm-blooded animals.
を傷部位に処理する、ヒト以外の温血動物の熱傷の治療
方法。19. A method for treating a burn of a warm-blooded animal other than a human, which comprises treating the wound site with an effective amount of the pharmaceutical composition according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06025840A JP3126583B2 (en) | 1994-01-13 | 1994-01-13 | Burn treatment agent, method for producing the same, and treatment method using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06025840A JP3126583B2 (en) | 1994-01-13 | 1994-01-13 | Burn treatment agent, method for producing the same, and treatment method using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07304684A JPH07304684A (en) | 1995-11-21 |
| JP3126583B2 true JP3126583B2 (en) | 2001-01-22 |
Family
ID=12177056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06025840A Expired - Lifetime JP3126583B2 (en) | 1994-01-13 | 1994-01-13 | Burn treatment agent, method for producing the same, and treatment method using the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3126583B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475742A (en) * | 2010-11-23 | 2012-05-30 | 天津天士力制药股份有限公司 | Application of residue obtained after oil extraction of inactivated poppy seed and extract thereof in preparation of analgesic medicine |
| JP2013502382A (en) * | 2009-08-20 | 2013-01-24 | ロンシャン スー | Use of a pharmaceutical composition in the preparation of a medicament for the treatment of diabetic ulcers |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19701264A1 (en) * | 1997-01-16 | 1998-07-23 | Kief Lizenz Verwertungsgesells | Remedies containing betasitosterol and / or phytosterol / betasitosteric mixtures |
| CN1827766B (en) * | 2001-06-28 | 2010-08-25 | 徐荣祥 | In vitro cell cultivation method |
| US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| JP2006096673A (en) * | 2004-09-28 | 2006-04-13 | Mihara Lr Kenkyusho:Kk | Method for producing earthworm product |
| JP2006249078A (en) * | 2005-02-10 | 2006-09-21 | Pure Green Kk | Emulsion drug formulation containing vegetable ingredient and its production method |
| KR101325608B1 (en) * | 2011-05-13 | 2013-11-06 | 김일광 | Compositions for burn treatment, and producing method of the same |
| CN103272017B (en) * | 2013-06-06 | 2015-04-01 | 马士滨 | Drug for treating burns and scalds |
| CN103610813B (en) * | 2013-11-26 | 2015-06-24 | 孙宝柱 | Externally-applied Chinese medicine formula for treating bedsore |
| CN114569692B (en) * | 2021-08-23 | 2023-06-20 | 杭州市红十字会医院 | Anti-infection traditional Chinese medicine composition and dressing for wound surface treatment and preparation method thereof |
-
1994
- 1994-01-13 JP JP06025840A patent/JP3126583B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502382A (en) * | 2009-08-20 | 2013-01-24 | ロンシャン スー | Use of a pharmaceutical composition in the preparation of a medicament for the treatment of diabetic ulcers |
| CN102475742A (en) * | 2010-11-23 | 2012-05-30 | 天津天士力制药股份有限公司 | Application of residue obtained after oil extraction of inactivated poppy seed and extract thereof in preparation of analgesic medicine |
| CN102475742B (en) * | 2010-11-23 | 2015-05-06 | 天士力制药集团股份有限公司 | Application of residue obtained after oil extraction of inactivated poppy seed and extract thereof in preparation of analgesic medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07304684A (en) | 1995-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0606786B1 (en) | A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human | |
| CN101879283A (en) | Novel membrane spraying preparation for skin trauma and preparation method | |
| MX2011007707A (en) | Use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer. | |
| JP3126583B2 (en) | Burn treatment agent, method for producing the same, and treatment method using the same | |
| CN1083268C (en) | Ointment for treating burn and scald and promoting tissue regeneration | |
| WO2017080048A1 (en) | Film spraying agent for superfical burns and preparation method therefor | |
| CN114392324A (en) | Bletilla striata medicine for treating burns and scalds and preparation method thereof | |
| CN105662996A (en) | Traditional Chinese medicine mask for treating menstruation-associated acne | |
| CN109820945B (en) | Composite medicine for promoting skin wound healing and hair growth and preparation method thereof | |
| CN1081925C (en) | Oil ointment of chirita longangensis for treating burns | |
| CN1058627C (en) | Compound arnebia root paste for curing heat injury of human body and its preparing method | |
| CN1068785C (en) | Chinese patent medicine for external application for curing diseases of scald, burn and dermal ulcer | |
| CN102846799A (en) | External traditional Chinese medicine paste for burn and scald treatment and preparation method thereof | |
| CN105233271A (en) | Anti-scaring andrias skin collagen burn cream and preparation method thereof | |
| CN111686167A (en) | Preparation method and application of antibacterial and anti-inflammatory ointment | |
| RU2337702C2 (en) | Balsam "gaysanovoy", possessing wound healing, antiinflammatory and anti-burn activity | |
| CN1156301C (en) | Ointment for treating burn and scald and its preparing process | |
| CN108853293B (en) | Compound essential oil for treating hemorrhoids and preparation method and use method thereof | |
| CN115414415B (en) | A Chinese medicinal composition for treating skin injury and ulcer, and its preparation method | |
| CN108524734A (en) | A kind of ointment for scald and preparation method thereof | |
| CN1229675A (en) | External-use ointment for treating burn | |
| Nasution et al. | The Effectiveness Comparison of Aloe Vera and Nothopanax Sutellarium Extract Toward Thermal Burn on White Rat (Rattus Norvegicus) | |
| CN1052907C (en) | Chinese herbal medicine for treating burn, and skin and external diseases and preparing process thereof | |
| KR100289906B1 (en) | Dermatological composition | |
| CN102178795B (en) | External medicine for treating burns and scalds and preparation method of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071102 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131102 Year of fee payment: 13 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |